Articles tagged with Brain Tumors
A study published in Nature found that glioma patients with hypermutated tumor cells did not benefit from checkpoint blocker treatments. The researchers suggest that approaches increasing cytotoxic lymphocyte infiltration may improve immunotherapy response in gliomas.
Researchers found that advancing glioma cells desynchronize neuronal activity and blood flow changes, affecting neurovascular coupling and potentially leading to seizures. The study provides promising targets for disrupting tumor growth and offers insights into diagnosis and surgical guidance.
A new optical imaging technology developed by Purdue University researchers may improve outcomes for patients with cancer and brain diseases. The technology uses contrast in light absorption to locate tumors and study neuron activation, providing more detailed information than current methods.
Gliomas alter astrocyte function, preventing the brain from removing excess excitatory chemicals, which can lead to seizures. The study found that scar-forming astrocytes surrounding tumors play a crucial role in this process.
A new study found that babies and young children with brain tumours tend to have better outcomes due to specific genetic weaknesses that can be targeted by existing drugs. Clinical trials are set to open to test the benefit of these precision medicines, offering a potential first-line treatment for infant brain tumours.
Researchers have identified a hereditary genetic defect that disrupts protein production in children with medulloblastoma, a common malignant brain tumor. The study found that 40% of children and young people with this subtype of medulloblastoma have a congenital genetic predisposition for the disease.
A study published in Neuro-Oncology Advances suggests that chemotherapy can be effective against diffuse intrinsic pontine glioma (DIPG), a devastating childhood brain cancer. Researchers found that the medicine reaches DIPG tissue in good quantities, offering new hope for treatment.
Researchers tested zika virus as a therapy for dogs with spontaneous brain tumors, achieving tumor reduction and longer survival. The treatment was well-tolerated and safe, with no adverse side effects.
A new Penn study found that imaging techniques, such as MRI, may help identify which glioblastoma patients are best candidates for liquid biopsies. The research showed a correlation between the blood-brain barrier and macrophage density with circulating DNA levels, suggesting the potential for personalized treatment decisions.
A retrospective study found that patients who underwent regular surveillance imaging after surgery had similar median survival rates to those who only returned when they felt symptoms of recurrence. The results suggest less frequent imaging could improve patient convenience and reduce costs.
A new simple blood test developed by the University of Bristol could help doctors diagnose brain tumors earlier, using fluorescent carbon dots and nanophotonics. The test aims to detect biomarkers such as Glial fibrillary acidic protein (GFAP) in blood samples.
Researchers at Case Western Reserve University and Cleveland Clinic have developed a new method to determine the relative life expectancy of glioblastoma patients using AI, MRI scans, and genomic analysis. This approach identifies patients who could benefit from experimental clinical trials.
Brazilian researchers analyze gene expression in medulloblastoma tumors from patients, finding all subtypes express stem cell markers BMI1 and CD133. They develop a novel combination therapy using epigenetic compound HDAC inhibitor to reduce tumor cell viability and cancer stem cell formation.
Scientists at Kanazawa University developed a novel method to detect invisible blood vessels inside tumors, which could help surgeons avoid hemorrhage during tumor resection. The new system uses a master-slave surgical robot with a force sensor that detects pulsation based on gripping force, even in soft and hard tumors.
Researchers at Johns Hopkins Kimmel Cancer Center found that combining TAK228 and trametinib may be more effective than either drug alone in decreasing pediatric low-grade glioma growth. The combination therapy also suppressed activity in key cell signaling pathways, reducing tumor growth and increasing survival in mice.
Researchers have found that a component of the Ebola virus can selectively target and kill glioblastoma brain tumors, providing a potential new approach to treating this deadly form of cancer. The Ebola glycoprotein MLD helps protect normal cells from infection while allowing cancer cells to be targeted by the immune system.
Researchers at Mayo Clinic have discovered a method to make tumor cells more responsive to immunotherapy. By promoting genetic mutations in tumor cells, they found that these cells become vulnerable to immune system attacks. The approach showed promise across different types of tumors and patient genomes.
A retrospective study by researchers at UC San Francisco found that removing the non-contrast-enhancing tumor increases survival for adults with glioblastoma. Patients with IDH-mutant tumors who underwent resections of both contrast-enhancing and non-contrast-enhancing tumor had a significantly longer average survival time, around 37.3...
Researchers developed an open-source app to interactively explore predictive algorithms for meningioma patients. The models effectively predicted outcomes in individual patients, but further refinements are needed using larger datasets.
Researchers developed a three-dimensional model that realistically models cancer mechano-biology while maintaining resolution power, enabling cost-effective simulations. The BioDynaMo platform provides a software platform for scientists and medics to create, run, and visualize 3D agent-based biological simulations.
Researchers at Houston Methodist have developed a new method for classifying pituitary tumors, which could improve diagnosis accuracy and treatment options. The test measures the levels of betahydroxybutyrate (BHB) in blood samples, indicating the presence of certain tumor subtypes.
Researchers at Duke University Medical Center have developed a poliovirus-based therapy that stimulates a natural immune attack on cancer cells in animal studies. The modified virus, called PVSRIPO, induces an immune response against mutated cancer cells found in diffuse midline glioma tumors, which are universally deadly in children.
A new study led by TGen suggests that tumor microenvironment plays a vastly under-studied role in cancer development and growth. By analyzing genetic sequencing, single-cell analysis, and high-resolution medical imaging, researchers can provide timely information on how to best attack each patient's cancer.
Researchers at Baylor College of Medicine discovered that brain tumors remodel neighboring neurons to promote tumor growth and seizure activity. Two variants of the PIK3CA gene drive this process, altering synaptic gene expression and inducing hyperexcitability in surrounding neurons.
The University of Trento led a research study to create in vitro tumor models using organoids, which can show signs of disease and provide a model of tumors affecting young patients. The study confirmed the key role of two proteins and investigated therapeutic options, making it possible to advance brain cancer research.
Researchers at the University of California - San Diego developed a new type of cancer model using genetically engineered human pluripotent stem cells. The model replicates the intra-tumor heterogeneity observed in patients and enables the study of tumor evolution, making it a potential platform for drug discovery.
Immune cells facilitate glioblastoma growth by clearing necrotic areas while ignoring tumour cells. Researchers aim to train microglia and macrophages for tumour elimination through immunotherapy or other strategies.
A recent study discovered a connection between glioma cells expressing the protein TAU and better patient outcomes. The presence of TAU helped regulate blood vessel formation, contributing to tumor aggression. Researchers suggest TAU levels could serve as a biomarker for tumor progression in IDH1/2 mutant gliomas.
A new study found that reinforcing the meningeal lymphatic network increases tumor antigen traffic from the meninges to lymph nodes, triggering activation of immune cells against the tumor. This approach combines with existing immunotherapy for effective glioblastoma eradication.
Scientists have found a novel method to combat glioblastoma, a deadly brain tumor, by introducing VEGF-C into the cerebrospinal fluid of mice. This approach significantly extended survival rates when combined with immune system checkpoint inhibitors, offering new hope for treatment options.
Researchers at Osaka University developed a machine-learning algorithm that uses MRI images to predict genetic mutations in glioma tumors. This breakthrough may lead to more suitable treatment for patients, giving better outcomes. The study was published in Scientific Reports.
Researchers found that surgically removing the entire tumor can boost median survival length from eight months to 16 months or more. The study analyzed data from 103 patients and suggests surgery may be a viable treatment option for brainstem high-grade gliomas, which are rare and deadly brain cancers.
Researchers develop biodegradable nanoparticles that target and kill pediatric brain tumor cells in mice, surviving 20-63% longer than untreated mice. The treatment uses a combination of the suicide gene and ganciclovir, showing promise for new therapies targeting these deadly brain malignancies.
A new study on brain tumors has identified mutations that are particular to different tumor types, enabling precision medicine approaches. The research also lists licensed drugs that could be used as combination therapies to target specific mutations in the future.
A novel method combining optical imaging with artificial intelligence produces accurate, real-time diagnosis of brain tumors. The system, stimulated Raman histology (SRH), reveals tumor infiltration and enables surgeons to see predicted diagnoses in under two minutes.
Researchers at Mount Sinai are exploring new treatments for brain tumors, including magnetic hyperthermia therapy and studies on glioma dormancy and tumor microenvironment. The grant funding will support five-year projects focused on improving patient outcomes through innovative therapies.
Researchers have developed glioblastoma organoids from patient tissue, allowing them to rapidly test personalized treatment strategies. The models retain features from the primary tumor and can be used to explore ways to attack it.
Scientists successfully deliver powerful glioblastoma drug paclitaxel into brain tumors in mice using an implantable ultrasound. The new formulation uses albumin instead of toxic cremophor, reducing brain toxicity. This technology has shown to increase drug concentrations by five-fold and prolong survival of brain tumor-bearing mice.
A study found that glioblastoma patients with a history of Human cytomegalovirus (HCMV) infection had a significantly shorter survival rate, highlighting the potential use of HCMV testing to predict treatment outcomes. The presence of HCMV antibodies was linked to a four-month reduction in life expectancy.
Researchers aim to overcome obstacles in brain tumor treatment by using focused ultrasound and temperature-sensitive nanoparticles. These strategies can provide unique opportunities to improve the delivery of nanoparticles into brain tumors.
A research team discovered that several types of highly aggressive and fatal pediatric brain tumors originate from stalled development of progenitor cells in the pons and forebrain. The cells' progress is arrested, and they transform into malignancies while retaining features of the original cells.
A research team identified that several types of highly aggressive pediatric brain tumors originate from stalled development of progenitor cells in the pons and forebrain. The findings represent a significant advance in understanding these diseases, which are the leading cause of cancer-related deaths in children.
The Ivy Brain Tumor Center is collaborating with SonALAsense to develop and test sonodynamic therapy, a promising new treatment for recurrent glioblastoma. The Phase 0/2 clinical trial will assess the safety and efficacy of this non-invasive therapy in patients with glioblastoma.
Researchers at Karolinska Institutet found that lithium can reverse cognitive problems caused by radiation damage in mice, improving memory capacity and learning capability. The study suggests a potential new treatment for damage caused by brain tumor radiotherapy.
Researchers have discovered that autophagy activity is essential to maintain high mTORC1 activity in cells with mutated genes, and blocking this process can mimic human TSC symptoms. This finding holds promise for developing new therapeutic concepts for treating patients with this devastating disease.
Researchers at HUG-CELL identified a microRNA inhibitor that reduces tumor size and improves survival in mice with aggressive brain tumors. The synthetic miR-367 inhibitor prevents the regulation of proteins involved in cell growth, leading to an attenuation of tumor aggressiveness.
Researchers developed an AI-powered blood test that can spot chemical clues indicative of brain tumors, allowing for quicker diagnoses and improved survival rates. The test, combining infrared spectroscopy with AI analysis, accurately identified 82% of brain tumors in a study of 400 patients.
Researchers at Karolinska Institutet have identified 10 novel glioblastoma-specific endothelial cell transcripts that could represent potential tumour-targets for therapy. The study uses a new method to process human brain tissue data and identifies disease-related changes in cells lining tumour blood vessels.
Researchers discovered a modified protein in benign-appearing meningiomas that can reveal which are truly benign and which are more dangerous. The finding may inform the discovery of drugs to treat these tumors more effectively.
A novel molecular marker has been identified for tumor aggression in neurofibromatosis type 1 (NF1), a rare genetic syndrome. ALT-positive tumors were found to be more aggressive, occurring mostly in gliomas.
A new study from Massachusetts General Hospital suggests that glowing particles in the blood of patients with brain cancer may be used to diagnose and monitor the disease. The discovery uses a substance called 5-aminolevulinic acid, which makes tumor cells fluorescent, allowing for non-invasive blood tests.
A new blood test has been developed to accelerate brain cancer diagnosis, distinguishing patients with brain cancer from healthy individuals correctly 87% of the time. The technology uses infrared light and artificial intelligence to identify the signs of cancer in a blood sample.
The study aims to examine the efficacy of a drug that inhibits an enzyme used by brain tumors to protect themselves from the immune response. Adding the inhibitor to chemotherapy and radiation therapy may enable lower doses, better quality of life, and improved survival for children with recurrent or newly diagnosed brain tumors.
Researchers at Baylor College of Medicine developed a reliable molecular profile for meningiomas, predicting tumor recurrence with high accuracy. The study identified a unique characteristic of aggressive meningiomas, the dysfunction of the DREAM complex, which contributes to malignant transformation.
Researchers have identified FGFR3 mutations in a subset of meningioma patients with favorable prognoses, suggesting potential for targeted therapy. These mutations may enhance diagnostic accuracy and clinical decision-making.
Researchers developed a 3D in vitro system to examine dynamic interactions between brain tumors and the surrounding extracellular matrix. The study found that fetal ECM supported tumor growth better than adult ECM, and lipid droplets released by glioblastoma cells may contribute to lower drug sensitivity.
Researchers at the Spanish National Research Council (CSIC) have found that glioblastoma hijacks pericytes to promote tumor progression and evade the immune system. By targeting chaperone-mediated autophagy, they may develop a new therapeutic approach to treat this aggressive brain cancer.
Researchers at Johns Hopkins Medicine developed a compound that extends survival in mice models of pediatric brain tumors, particularly those expressing the MYC oncogene. The compound inhibits glutamine metabolism, making chemotherapy more effective.
Researchers at Cedars-Sinai have developed a rapid method to genetically alter laboratory mice, producing personalized models of complex cancers. The technique overcomes drawbacks in current techniques and can be used to modify patient-derived cells.
Researchers at Stanford University School of Medicine discovered that severe brain cancers form synapses with healthy neurons, hijacking electrical signals to drive their own growth. The study found that interrupting these signals with an anti-epilepsy drug greatly reduced tumor growth in human tumors in mice.